Skip to main content

 Related scientific articles (all)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.

Authors : Agostinetto E, Montemurro F, Puglisi F, Criscitiello C, Bianchini G, Del Mastro L, Introna M, Tondini C, Santoro A, Zambelli A
Year : 2022
Journal : Cancers (Basel)
Volume : 14

Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: Enough Data to be Considered Effective?

Authors : Hadefi A, Gkolfakis P, Devière J
Year : 2022
Journal : Clin Gastroenterol Hepatol
Volume : 20
Pages : 1186-1187

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Authors : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3

Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?

Authors : Sclafani F, Hendlisz A
Year : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 379-381

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.

Authors : Schöffski P, Awada A, de la Bigne AM, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S
Year : 2022
Journal : Eur J Cancer
Volume : 169
Pages : 135-145

Patient-reported outcomes in terms of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy: Swall PEG

Authors : Dragan T, Van Gossum A, Duprez F, Lalami Y, Lefebvre Y, Mootassim-Billah S, Beauvois S, Gulyban A, Vandekerkhove C, Boegner P, Paesmans M, Ameye L, Digonnet A, Quiriny M, Dequanter D, Lipski S, Willemse E, Rodriguez A, Carlot S, Karaca Y, Lemort M, Emonts P, Al Wardi C, Van Gestel D
Year : 2022
Journal : Trials
Volume : 23
Pages : 1036

JCOG0603: Are We Really Sure This Was a Negative Trial?

Authors : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F
Year : 2022
Journal : J Clin Oncol
Volume : 40
Pages : 803-805

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.

Authors : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F
Year : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 382-388

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.

Authors : Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP
Year : 2022
Journal : Clin Cancer Res
Volume : 28
Pages : 2762-2770

Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.

Authors : Khan SZ, Arecco L, Villarreal-Garza C, Sirohi B, Ponde NF, Habeeb B, Brandão M, Azim HA Jr, Chowdhury AR, Bozovic-Spasojevic I, Kovalenko I, Odhiambo A, Seid FU, Mutombo AB, Petracci F, Vidra R, Altuna SC, Petrova M, Kourie HR, Ozturk MA, Razeti MG, Lengyel CG, Talibova N, Mariamidze E, Sacardo KP, Duma N, Gyawali B, Trapani D, Tagliamento M, Lambertini M
Year : 2022
Journal : JCO Glob Oncol
Volume : 8
Pages : e2100153

Molecular oncology: what is needed to speed access to innovative therapies in clinical research?

Authors : Gourari K, Awada A, Kotecki N
Year : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 575-578

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors : Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, Van De Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S
Year : 2022
Journal : Ann Oncol
Volume : 33
Pages : 20-33

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.

Authors : Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E
Year : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pages : 1117-1126

Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel.

Authors : Martel S, Lambertini M, de Azambuja E
Year : 2022
Journal : J Natl Compr Canc Netw
Volume : 20
Pages : xlv-xlvi

Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group.

Authors : Sclafani F, Fontana E, Wyrwicz L, Wagner AD, Valle JW, Smyth E, Peeters M, Obermannova R, Neuzillet C, Lutz MP, Koessler T, Ben-Aharon I, Arnold D, Alsina M, Moehler M
Year : 2022
Journal : Clin Colorectal Cancer
Volume : 21
Pages : 188-197

Erratum to Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]."

Authors : Piccart MJ, Kalinsky K, Gray R, Barlow WE, Poncet C, Cardoso F, Winer E, Sparano J
Year : 2022
Journal : Ann Oncol
Volume : 33
Pages : 668

How we treat patients with metastatic HER2-positive breast cancer.

Authors : Nader-Marta G, Martins-Branco D, de Azambuja E
Year : 2022
Journal : ESMO Open
Volume : 7
Pages : 100343

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.

Authors : Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL
Year : 2022
Journal : Clin Cancer Res
Volume : 28
Pages : 3452-3463

Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab.

Authors : Orte Cano C, Van Meerhaeghe T, Tannous J, Lienard D, Van Gestel D, Cuylits N, Luce S, Carlot S, Le Moine A, Aspeslagh S, Del Marmol V
Year : 2022
Journal : J Eur Acad Dermatol Venereol
Volume : 36 Suppl 1
Pages : 53-58

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.

Authors : Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D
Year : 2022
Journal : Cancer Treat Rev
Volume : 111
Pages : 102468